Full-Time
Associate Sales Representative
Interventional Spine
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
Compensation Overview
$70k/yr
Company Historically Provides H1B Sponsorship
Dallas, TX, USA
In Person
Field-based role with approximately 20% travel.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Stryker
See people who can refer or advise you
- A Bachelor's Degree from an accredited university is required.
- One to two years of experience in medical sales or business-to-business sales is preferred.
- A valid driver's license and the ability to drive an automobile are required.
- The role requires the ability to exert up to 50 pounds of force occasionally and/or up to 20 pounds constantly to move objects.
- The role requires coordination of eye, hand, and foot movements, the ability to grasp by hand, and visual and auditory discrimination, memory, reading ability, and memory retention.
- The role requires discretion and independence when applying professional expertise.
- The role requires the ability to manage time, projects, stress, and conflict.
- Strong written and oral communication skills are required.
- The role requires completing tasks with minimal supervision.
- The role requires prioritizing work and keeping detailed and confidential records.
- The role requires communicating and presenting to large groups of people.
- Unwavering ethics and integrity are required in a competitive and demanding work environment.
- Strategically promote and sell Interventional Spine products to meet customer needs.
- Conduct product evaluations in operating room and office settings and demonstrate the value of products.
- Track territory progress, communicate wins with Sales Representatives, and work to exceed performance goals.
- Use product knowledge and quick thinking onsite with clients to solve product problems.
- Inform doctors, nurses, and other staff about the proper use and maintenance of products.
- Provide excellent customer service and assist customers whenever needed.
- One to two years of experience in medical sales or business-to-business sales.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 organic sales rose 9%, with strong MedSurg and Orthopaedics growth.
- AVS closed in Q2 2026, expanding peripheral vascular exposure and salesforce leverage.
- Management raised 2026 outlook to 8.3%-9.3% organic growth and $14.95-$15.10 EPS.
What critics are saying
- March 2026 cyberattack disrupted manufacturing, delayed shipments, and exposed operational fragility.
- Peripheral vascular supply disruption created Q2 2026 backorders, with recovery targeted only by Q3.
- Any repeat cyber incident or plant outage would hit revenue and threaten 2026 guidance.
What makes Stryker unique
- Mako robotics keeps winning installations and supports Stryker's orthopedic workflow lock-in.
- Stryker spans MedSurg, Neurotechnology, and Orthopaedics, cushioning demand across procedure types.
- Pangea Plating and TPX HD show a steady, surgeon-led product launch cadence.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.
Stryker reported Q2 revenue of $6.59 billion, up 9.4% year on year, meeting Wall Street expectations. The medical technology company's non-GAAP earnings of $3.69 per share beat analyst estimates by 5.8%. Despite meeting forecasts, investors reacted negatively due to supply chain disruptions in the peripheral vascular business. Chief executive Kevin Lobo said the quarter focused on recovery from a recent cybersecurity incident, which caused production disruptions and elevated backlogs. The company expects backorders to normalise by the end of Q3. Management cited strong demand for capital equipment and Mako robotics, which saw record Q2 installations. Operating margin expanded to 25.2% from 18.5% last year, supported by operational discipline and efficiency initiatives. Management slightly raised full-year adjusted earnings guidance.
Stryker reported strong second-quarter 2026 results with 9% organic sales growth, driven by high single-digit gains in both its med surg and neurotechnology and orthopaedics businesses. The medical device company is recovering from a cybersecurity incident whilst ramping up production to meet demand. In the US, Stryker achieved 9% organic sales growth, with double-digit expansion in its medical, trauma extremities, and endoscopy divisions. The company's OrthoTech and instruments segments posted high single-digit growth. However, supply disruptions affected the peripheral vascular business, creating a significant backorder situation and lost sales. Stryker expects to resolve these issues by the end of the third quarter. The company also completed its acquisition of AVS during the quarter and remains confident in the long-term outlook for its peripheral vascular business.
Stryker Corporation reported second quarter 2026 results, with net sales rising 9.4% to $6.6 billion and organic sales up 9.0%. The medical technology company's adjusted earnings per share increased 17.9% to $3.69, whilst reported EPS jumped 44.1% to $3.30. The company's MedSurg and Neurotechnology division posted sales of $3.6 billion, up 9.7%, with organic growth of 9.2%. Orthopaedics sales reached $3.0 billion, increasing 9.1%. Chair and CEO Kevin Lobo attributed the strong performance to recovery from a cyber incident, noting the company's resilience. Adjusted operating margin improved 170 basis points to 27.4%. Stryker expressed confidence in maintaining growth at the high end of the medical technology sector for the second half of 2026.
Stryker reported $6.02 billion in revenue for Q1 2026, missing the $6.33 billion consensus following a March cyberattack, whilst Intuitive Surgical beat expectations with $2.77 billion in revenue, up 23%, and earnings per share of $2.50 against a $2.11 consensus. Despite the cyberattack impact, Stryker's core businesses remained strong, with its Mako-driven orthopaedics franchise growing and its Vascular division jumping 27.5% following the Inari acquisition. The company maintained full-year guidance of 8% to 9.5% organic growth and delivered free cash flow of $415 million, up 227%. Stryker trades at approximately 22 times forward earnings compared to Intuitive Surgical's 39 times, as da Vinci procedure growth guidance steps down from 18% to roughly 15%.